Universal Diagnostics S.A.

Universal Diagnostics S.A. announces a €20 million financing from the European Investment Bank (EIB) to support the development and commercialization of our cutting-edge blood-based liquid biopsy solutions for early cancer detection. This financing, backed by the #InvestEU program, will accelerate the expansion of our most advanced product, Signal-C® for colorectal cancer screening, as well as the development of Signal-Li and Signal-Lu for liver and lung cancer, respectively. It will also support our U.S. clinical trial for FDA approval and reimbursement, bringing us closer to offering a non-invasive, highly accurate cancer screening solution. At Universal DX, our mission is to transform cancer into a curable disease by detecting it early. Our proprietary technology, which combines next-generation sequencing, methylation, fragmentation, and microbiome biomarkers with AI-driven bioinformatics, is at the forefront of innovation in the MedTech space. “With the transformative power of our technology, we are taking bold steps toward our vision of making cancer a curable disease. The support from the EIB will enable us to bring our revolutionary blood tests to both European and U.S. markets.” – Juan Martinez-Barea, Founder and Chairman of Universal DX This funding also contributes to Europe’s Beating Cancer Plan, reinforcing the EIB’s commitment to technological innovation in healthcare. #CancerDetection #LiquidBiopsy #EIB #InvestEU

💡 Exciting research update! Thrilled to share that our latest study on #colorectal #adenoma subtypes and their unique molecular profiles has been published in Cancers MDPI! This work sheds light on critical molecular alterations that could improve early detection strategies for colorectal cancer—a step forward in precision medicine. Honored to be part of this fantastic team at Universal Diagnostics S.A. and collaborate with incredible researchers. Check out the full article here: https://lnkd.in/dS2z4ZUT #ColorectalCancer #EarlyDetection #CancerResearch #WeWillWinTheFightAgainstCancer

We are pleased to announce that our latest research, "Colorectal Adenoma Subtypes Exhibit Signature Molecular Profiles: Unique Insights into the Microenvironment of Advanced Precancerous Lesions for Early Detection Applications," has been accepted and published in Cancers MDPI as part of their Special Issue "Emerging Therapies in the Management of Gastrointestinal Malignancies." 🔬 This study provides a deep dive into the molecular landscape of colorectal #adenoma subtypes, revealing distinct DNA methylation patterns, copy number variations, and genetic mutations. These insights offer valuable opportunities to enhance early detection and prevention strategies for colorectal cancer. 📖 Read the full article: https://lnkd.in/dS2z4ZUT Thank you to our incredible research team Francesco Mattia Mancuso, Juan Carlos H., Pol Canal Noguer, Arianna Bertossi, Alexandre Perera LLuna from Universitat Politècnica de Catalunya (UPC), Michael Herbert Alexander Roehrl from Beth Israel Deaconess Medical Center & Kristi Kruusmaa for their dedication and expertise. At Universal Diagnostics S.A., we remain committed to pioneering innovative approaches for the early detection of cancer. #ColorectalCancer #EarlyDetection

Thrilled to be a part of #aacrLBx24 and excited to showcase our collaboration with Universal Diagnostics S.A. in developing an innovative early-detection workflow for colorectal cancer. #Epigenomics #BiomarkerDiscovery #LiquidBiopsy

Universal Diagnostics S.A. has been featured in Startup to Follow for our revolutionary approach to colorectal cancer screening. 🧬 Signal-C, our cutting-edge blood-based test, is transforming early detection, providing a non-invasive and highly accurate solution. Check out the full article below. Thank you to Startup to Follow. #ColorectalCancer #EarlyDetection #InnovationInHealthcare #SignalC #MedTech #HealthcareTransformation

Exciting News from Universal Diagnostics S.A. at ISDE World Congress 2024! 🚀 We are thrilled to announce that our abstract was selected for the prestigious Oral Poster of Distinction Presentation at the ISDE World Congress 2024 in Edinburgh, Scotland! 🎉 From September 22-24, our talented colleague, Nastaran Riahi Dehkordi, shared insights into Universal Diagnostics’ pioneering approach to the future of #esophageal cancer detection and treatment. The abstract has been published in the Diseases of the Esophagus Journal and is now available on the Oxford Academic platform. You can read it here: https://lnkd.in/dNi7WauA Great work, Juan Carlos H.! #ISDEWorldCongress #EsophagealCancer #CancerResearch #InnovationInHealth #MedicalAdvancements

Universal Diagnostics S.A. announces the completion of the funding required for the Signal-C® FDA premarket approval with existing investors, including Quest Diagnostics, and new investors, including Olympus Innovation Ventures. The clinical trial for Signal-C® (https://lnkd.in/dVxuMvxj) is well underway and recruited its first patient in January 2024. The study is on target to reach its recruiting goal of enrolling at least 15,000 patients across 100 investigator sites. Quest Diagnostics operates an oncology center of excellence in Lewisville, Texas, that will serve as the single site for testing for the trial. The parties announced a collaboration in November 2023 under which Quest will have exclusive rights to provide clinical laboratory services in the U.S. assuming FDA approval for the test. UDX is the provider of the results of the assay through its proprietary cloud solution. Once FDA approved, both parties will commercialize the test. “We are thrilled to announce the start of our FDA validation for Signal-C®,” said Juan Martinez-Barea, Chairman of UDX. “After securing the funding required, and having operationally launched our collaboration with Quest, UDX is one step closer to reaching the market with a non-invasive, highly accurate blood test for screening for colorectal cancer. Early detection is crucial, and our technology has the potential to significantly reduce the mortality of this disease.” #liquidbiopsy #FDA #PROMISE #SignalC #colorectalcancer #screening #earlydetection

Universal Diagnostics S.A. announces the completion of the funding required for the Signal-C® FDA premarket approval with existing investors, including Quest Diagnostics, and new investors, including Olympus Innovation Ventures. The clinical trial for Signal-C® (https://lnkd.in/dVxuMvxj) is well underway and recruited its first patient in January 2024. The study is on target to reach its recruiting goal of enrolling at least 15,000 patients across 100 investigator sites. Quest Diagnostics operates an oncology center of excellence in Lewisville, Texas, that will serve as the single site for testing for the trial. The parties announced a collaboration in November 2023 under which Quest will have exclusive rights to provide clinical laboratory services in the U.S. assuming FDA approval for the test. UDX is the provider of the results of the assay through its proprietary cloud solution. Once FDA approved, both parties will commercialize the test. “We are thrilled to announce the start of our FDA validation for Signal-C®,” said Juan Martinez-Barea, Chairman of UDX. “After securing the funding required, and having operationally launched our collaboration with Quest, UDX is one step closer to reaching the market with a non-invasive, highly accurate blood test for screening for colorectal cancer. Early detection is crucial, and our technology has the potential to significantly reduce the mortality of this disease.” #liquidbiopsy #FDA #PROMISE #SignalC #colorectalcancer #screening #earlydetection

Our amazing team at #AACR Annual Meeting 2024 in San Diego! Kristi Kruusmaa Francesco Mattia Mancuso Pol Canal Noguer Vivian Erklavec Zajec Arianna Bertossi, Ph.D Arne Gouwy #WeWillWinTheFightAgainstCancer #ColorectalCancer #Screening #EarlyDetection #Prevention